Reuters logo
BRIEF-Oncolytics Biotech and Adlai Nortye enter into $86.6 mln regional licensing agreement for Reolysin
November 16, 2017 / 10:14 PM / a month ago

BRIEF-Oncolytics Biotech and Adlai Nortye enter into $86.6 mln regional licensing agreement for Reolysin

Nov 16 (Reuters) - Oncolytics Biotech Inc

* Oncolytics Biotech® Inc. and Adlai Nortye enter into $86.6 million regional licensing agreement for Reolysin®

* Oncolytics Biotech Inc - ‍Oncolytics to receive upfront, licensing fee and milestone payments to support phase 3 registration study of usd $21.2 million​

* Oncolytics Biotech - ‍Co is eligible to receive up to additional $65.4 million upon achievement of clinical, regulatory, commercialization milestones​

* Oncolytics Biotech Inc - ‍Upon Adlai Nortye’s commercialization of reolysin, Oncolytics is eligible to receive double digit royalty payments​

* Oncolytics - Adlai to have exclusive development, commercialization rights to Reolysin in China, Hong Kong, Macau, Singapore, South Korea and Taiwan​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below